Tag:
Teva Pharmaceutical Industries
Latest Headlines
Latest Headlines
Amid $2B in cost-cutting, Teva sales suffer from generic erosion
Teva Pharmaceutical Industries may be a generics behemoth, but its earnings this quarter bore a more-than-casual resemblance to Big Pharma's.
OPKO Health to acquire Prolor Biotech for $480M
OPKO Health announced today that it is poised to acquire Israel-based Prolor Biotech in an all-stock transaction valued at $480 million, or $7 per share of Prolor common stock.
OxyContin patent expires Tuesday but FDA under pressure to stall generics
Purdue's original patent on the superpotent and often abused painkiller OyxContin expires tomorrow, and drugmakers are jockeying for a piece of its $2.8 billion market share. But the FDA is under increasing pressure to require generic drugmakers to make their formulations tamper-resistant.
Fierce's 10 top biotech billionaires
They are already rich, so why spotlight billionaires like Microsoft Chairman Bill Gates and Teva Chairman Dr. Phillip Frost ? Well, the mega-wealthy have made an impact all over the biopharma world,...
AZ's Pulmicort patent loss could cost $100M-plus
A U.S. court has ruled against AstraZeneca in a long-running patent fight over its asthma drug Pulmicort Respules. That means copycat drugmakers can launch their versions, competing with Teva Pharmaceutical's authorized generic.
New math on biosimilars sends a chilling message to Lonza/Teva team
Late last year Lonza and Teva sent a chill down the backs of an emerging group of developers working on biosimilars--those follow-on therapies that are expected to take the price of aging biologics down a peg or two as they lose patent protection.
Teva touts fresh PhIII evidence of oral MS drug's potential
Teva and its multiple sclerosis partner Active Biotech rolled out some new top-line Phase III data on their troubled program for the oral multiple sclerosis drug laquinimod--still Teva's best shot at protecting the $4 billion franchise built up for Copaxone.
Israel should brace itself for Teva job cuts, analysts say
Teva Pharmaceutical Industries Chairman Philip Frost is warning that the drugmaker can no longer operate as it did in the "good old days ." Teva is a global pharma company with bigger ambitions, and it has to act like one--even when those ambitions include possible job cuts, apparently.
Teva retrenches on troubled MS blockbuster hopeful as partner grabs $43M
Just as Active Biotech's big pharma partner Teva enrolled the first person in its high-stakes gamble on the third big Phase III study for the oral MS drug laquinimod, the Swedish biotech company announced that it had raked in $43 million from a wealthy family.
Biosimilars face big delays as blockbuster knockoffs hit a roadblock
The news on the biosimilar R&D front has been all bad in recent months--at least for the biggest players in the business. Merck, Teva and Samsung have all experienced severe setbacks, scrapping follow-on programs for some of the biggest biologic targets now on the market.
